Literature DB >> 25937767

Mesopancreas in pancreatic cancer: where do we stand - review of literature.

Ramachandra Chowdappa1, Vasu Reddy Challa2.   

Abstract

Pancreatic cancer is associated with poor prognosis and surgery remains the main modality of treatment. Negative resection margin is an important prognostic factor for survival. Retropancreatic margin or the medial margin is the most common site of positive resection margin. Mesopancreas was proposed in analogy with mesorectum, which is considered as a fusion fascia formed embryologically during the development of pancreas. This mesopancreas lies posterior to the pancreas and contains pancreaticoduodenal vessels, lymphatics, nerve plexus and loose areolar tissue. Various technical modifications were proposed for better dissection of mesopancreas like posterior approach and artery first approach. There is an increased rate of R0 resection by these technical modifications but whether this will turn to increase in survival rates is yet to be established.

Entities:  

Keywords:  Mesopancreas; Retropancreatic lamina; Retroportal lamina; Total mesopancreatic excision

Year:  2014        PMID: 25937767      PMCID: PMC4412854          DOI: 10.1007/s13193-014-0294-7

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  39 in total

1.  Development and progress in resective surgery for pancreatic cancer.

Authors:  J M Howard
Journal:  World J Surg       Date:  1999-09       Impact factor: 3.352

Review 2.  Survival statistics gone awry: pancreatic cancer, a case in point.

Authors:  Birgir Gudjonsson
Journal:  J Clin Gastroenterol       Date:  2002-08       Impact factor: 3.062

3.  The "artery first" approach for resection of pancreatic head cancer.

Authors:  Jürgen Weitz; Nuh Rahbari; Moritz Koch; Markus W Büchler
Journal:  J Am Coll Surg       Date:  2009-12-03       Impact factor: 6.113

4.  Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial.

Authors:  Helmut Oettle; Stefan Post; Peter Neuhaus; Klaus Gellert; Jan Langrehr; Karsten Ridwelski; Harald Schramm; Joerg Fahlke; Carl Zuelke; Christof Burkart; Klaus Gutberlet; Erika Kettner; Harald Schmalenberg; Karin Weigang-Koehler; Wolf-Otto Bechstein; Marco Niedergethmann; Ingo Schmidt-Wolf; Lars Roll; Bernd Doerken; Hanno Riess
Journal:  JAMA       Date:  2007-01-17       Impact factor: 56.272

5.  Appraisal of a total meso-pancreatoduodenum excision with pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Y Kawabata; T Tanaka; T Nishi; H Monma; S Yano; Y Tajima
Journal:  Eur J Surg Oncol       Date:  2012-05-09       Impact factor: 4.424

6.  Redefining the R1 resection in pancreatic cancer.

Authors:  C S Verbeke; D Leitch; K V Menon; M J McMahon; P J Guillou; A Anthoney
Journal:  Br J Surg       Date:  2006-10       Impact factor: 6.939

7.  Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience.

Authors:  Axel Richter; Marco Niedergethmann; Jörg W Sturm; Dietmar Lorenz; Stefan Post; Michael Trede
Journal:  World J Surg       Date:  2003-02-27       Impact factor: 3.352

8.  Total pancreatectomy (R0 resection) improves survival over subtotal pancreatectomy in isolated neck margin positive pancreatic adenocarcinoma.

Authors:  C Max Schmidt; Jeffrey Glant; Jordan M Winter; Jason Kennard; Jennifer Dixon; Qianqian Zhao; Thomas J Howard; James A Madura; Atilla Nakeeb; Henry A Pitt; John L Cameron; Charles J Yeo; Keith D Lillemoe
Journal:  Surgery       Date:  2007-10       Impact factor: 3.982

9.  Preliminary experience with the hanging maneuver for pancreaticoduodenectomy.

Authors:  P Pessaux; E Rosso; F Panaro; E Marzano; E Oussoultzoglou; P Bachellier; D Jaeck
Journal:  Eur J Surg Oncol       Date:  2009-05-06       Impact factor: 4.424

10.  The mesorectum in rectal cancer surgery--the clue to pelvic recurrence?

Authors:  R J Heald; E M Husband; R D Ryall
Journal:  Br J Surg       Date:  1982-10       Impact factor: 6.939

View more
  7 in total

1.  Systematic review of the mesopancreas: concept and clinical implications.

Authors:  J M Ramia; R De-la-Plaza; A Manuel-Vazquez; A Lopez-Marcano; R Morales
Journal:  Clin Transl Oncol       Date:  2018-04-19       Impact factor: 3.405

Review 2.  What do surgeons need to know about the mesopancreas.

Authors:  Eduardo de Souza M Fernandes; Oliver Strobel; Camila Girão; Jose Maria A Moraes-Junior; Orlando Jorge M Torres
Journal:  Langenbecks Arch Surg       Date:  2021-06-12       Impact factor: 3.445

3.  Laparoscopic uncinate process first pancreatoduodenectomy-feasibility study of a modified 'artery first' approach to pancreatic head cancer.

Authors:  Michał Pędziwiatr; Magdalena Pisarska; Piotr Małczak; Piotr Major; Mateusz Wierdak; Dorota Radkowiak; Jan Kulawik; Marcin Dembiński; Andrzej Budzyński
Journal:  Langenbecks Arch Surg       Date:  2017-07-11       Impact factor: 3.445

4.  Modified Heidelberg technique of pancreatic anastomosis postpancreaticoduodenectomy - 10 years of experience.

Authors:  Ramachandra Chowdappa; Ajeet Ramamani Tiwari; Namrata Ranganath; Rekha V Kumar
Journal:  South Asian J Cancer       Date:  2019 Apr-Jun

5.  Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution.

Authors:  Qi Li; Zijian Feng; Ruyi Miao; Xun Liu; Chenxi Liu; Zhen Liu
Journal:  World J Surg Oncol       Date:  2022-01-07       Impact factor: 2.754

6.  Total mesopancreas excision for the treatment of pancreatic head cancer.

Authors:  Jingyong Xu; Xiaodong Tian; Yiran Chen; Yongsu Ma; Chang Liu; Long Tian; Jianwei Wang; Jianqiang Dong; Di Cui; Yang Wang; Weiguang Zhang; Yinmo Yang
Journal:  J Cancer       Date:  2017-09-30       Impact factor: 4.207

7.  Can Elderly Patients With Pancreatic Cancer Gain Survival Advantages Through More Radical Surgeries? A SEER-Based Analysis.

Authors:  Danna Xie; Baolin Qian; Jing Yang; Xinya Peng; Yinghua Li; Teng Hu; Simin Lu; Xiaojing Chen; Yunwei Han
Journal:  Front Oncol       Date:  2020-10-29       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.